id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-N-0238-0019,FDA,FDA-2006-N-0238,Letter from Cancer Leadership Council (CLC) to  FDA /CDER,Other,Letter(s),2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,,2025-04-11T22:27:16Z,,0,0,0900006480744556
FDA-2006-N-0238-0018,FDA,FDA-2006-N-0238,OMB Changes of the Proposed Rule FDA Regulations Policy and Management Staff to the Division of Dockets Management,Supporting & Related Material,Reference (internal unless indicated),2008-10-14T04:00:00Z,2008,10,,,2025-04-14T17:07:08Z,,0,0,0900006480456b60
FDA-2006-N-0238-0017,FDA,FDA-2006-N-0238,Reference 1 OMB Changes of FDA Regulations Policy and Management Staff to the Division of Dockets Management,Supporting & Related Material,Reference (internal unless indicated),2008-10-10T04:00:00Z,2008,10,,,2025-04-14T16:59:59Z,,0,0,0900006480456cc2